Imaging consensus tightens the role of CT, MRI, and molecular scans in primary aldosteronism
An international, multidisciplinary consensus has drawn a clearer map for how imaging should be used in primary aldosteronism, a disorder in which autonomous aldosterone production drives hypertension and potassium wasting. The new PAIO consensus focuses on a practical question that has long shaped endocrine and surgical decision-making: when imaging is used to localize disease, how much confidence can clinicians place in what they see, and how should those findings influence treatment selection for unilateral adrenalectomy?
The panel addressed three clinical problems that sit at the center of everyday management. First, it examined which radiologic features define normal adrenal morphology versus abnormal morphology in primary aldosteronism. Second, it compared the imaging patterns seen in lateralized and non-lateralized disease. Third, it assessed how well features on CT, MRI, and molecular imaging predict biochemical remission after unilateral adrenalectomy. Those questions matter because imaging in this disease is not just descriptive; it is used to decide whether a patient proceeds to surgery or remains on medical therapy.
Primary aldosteronism is clinically important because excessive aldosterone acts on the kidney to retain sodium, expand volume, and suppress potassium. In unilateral disease, the source can often be removed surgically, but the path from biochemical diagnosis to operative cure is rarely straightforward. Adrenal nodules are common, incidental findings are common, and not every structural abnormality produces hormonally dominant disease. The consensus addresses this mismatch directly by framing imaging as one component of a broader therapeutic pathway rather than a stand-alone arbiter.
A single adrenal image rarely answers the whole clinical question.
Morphology alone cannot substitute for endocrine localization
The consensus places strong emphasis on the difference between adrenal morphology and functional laterality. Conventional CT and MRI can identify size, shape, and visible nodules, but those anatomic details do not reliably establish whether aldosterone excess arises from one gland or both. In practice, this distinction is critical because unilateral adrenalectomy offers the possibility of biochemical remission, while bilateral disease generally requires ongoing medical management.
The panel’s review of the imaging literature reinforces a familiar limitation of structural imaging: abnormal morphology does not always mean the lesion is the hormonal driver. Small adrenal nodules may be incidental, while hormonally active disease can exist without a dramatic structural abnormality. For clinicians, this means imaging must be interpreted in the context of the underlying endocrine phenotype, not in isolation. The consensus therefore serves as a guardrail against overcalling a visible adrenal lesion as the source of aldosterone excess.
CT, MRI, and molecular imaging each answer a different question
The recommendations address CT-, MRI-, and molecular imaging-based approaches together rather than treating them as interchangeable tools. CT and MRI remain central for visualizing adrenal anatomy and for identifying gross asymmetry or lesions that may support later procedural planning. Molecular imaging, by contrast, is positioned as part of a more refined localization strategy when conventional studies leave uncertainty about the source of secretion.
This layered approach reflects the biology of primary aldosteronism. Excess aldosterone is a functional disorder first and an anatomic disorder second. Imaging that can only detect structure will inevitably miss some cases of hormonally active disease or overinterpret lesions that are not truly causal. By incorporating molecular techniques into the discussion, the consensus acknowledges that tissue function, not just tissue shape, is what ultimately matters when surgery is being considered.
The practical consequence is straightforward: imaging should be used to improve selection for unilateral adrenalectomy, not to replace clinical and biochemical evaluation. In a disease where the treatment pathway hinges on identifying laterality, a scan that is visually impressive but biologically noninformative can mislead as easily as it can help.
Predicting biochemical remission after unilateral adrenalectomy remains the central test
One of the most consequential questions in the consensus is whether CT, MRI, and molecular imaging can predict biochemical remission after unilateral adrenalectomy. That endpoint is more than academic. For patients, remission means the surgery treated the hormonal excess rather than simply removing a visible adrenal abnormality. For clinicians, it is the closest confirmation that the preoperative localization strategy was correct.
The consensus reviews the reliability of imaging features for this purpose and, by framing the question explicitly, places emphasis on outcome rather than appearance. A visible lesion on CT or MRI may support surgical planning, but the key test is whether the lesion identifies the gland responsible for the aldosterone excess. Molecular imaging may improve confidence in select cases, yet the consensus does not suggest that any one modality should be used reflexively or in isolation.
This approach is especially relevant in patients with lateralized disease, where a unilateral operation may offer the greatest chance of cure, and in non-lateralized disease, where surgery is less likely to produce the desired biochemical response. Imaging patterns can vary across these subtypes, and the consensus aims to translate those differences into practical bedside decisions.
Imaging recommendations now sit closer to procedure selection
The PAIO consensus is less about introducing a brand-new technology than about organizing existing tools into a clearer clinical sequence. By setting out graded recommendations and key summary points, the panel gives clinicians a framework for choosing among CT, MRI, and molecular imaging when evaluating patients with primary aldosteronism. The message is not that every patient needs every scan, but that imaging should be selected and interpreted with the anticipated treatment pathway in mind.
For surgeons, endocrinologists, and radiologists, the main implication is that imaging findings must be integrated with the biochemical workup before unilateral adrenalectomy is pursued. For patients, the immediate relevance is equally concrete: the quality of imaging interpretation may determine whether a potentially curative operation is offered, deferred, or avoided.
The consensus does not eliminate uncertainty around localization, and it does not turn imaging into a perfect predictor of cure. It does, however, provide a structured way to ask which test is being used, what question it can legitimately answer, and how much weight its findings should carry when a unilateral adrenalectomy is under consideration. PMID 43045815 anchors the statement in the peer-reviewed literature and places the recommendations within the current evidence base for endocrine hypertension.
- • PubMed PMID 43045815: https://pubmed.ncbi.nlm.nih.gov/43045815/